Send to

Choose Destination
JACC Cardiovasc Interv. 2014 Jan;7(1):89-99. doi: 10.1016/j.jcin.2013.07.007. Epub 2013 Oct 16.

A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.

Author information

Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium. Electronic address:
Mercy Angiography Unit, Auckland, New Zealand; Auckland City Hospital, Auckland, New Zealand.
Auckland City Hospital, Auckland, New Zealand.
Antwerp Cardiovascular Center, ZNA Middelheim, Antwerp, Belgium.
Cardiovascular Research Center, Sao Paulo, Brazil.
Elixir Medical Corporation, Sunnyvale, California.



This study sought to perform clinical and imaging assessments of the DESolve Bioresorbable Coronary Scaffold (BCS).


BCS, which is drug eluting, may have potential advantages compared with conventional metallic drug-eluting stents. The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus.


The DESolve First-in-Man (a non-randomized, consecutive enrollment evaluation of the DESolve myolimus eluting bioresorbable coronary stent in the treatment of patients with de novo native coronary artery lesions) trial was a prospective multicenter study enrolling 16 patients eligible for treatment. The principal safety endpoint was a composite of cardiac death, myocardial infarction, and clinically indicated target lesion revascularization. The principal imaging endpoint was in-scaffold late lumen loss (LLL) assessed by quantitative coronary angiography (QCA) at 6 months. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging was performed at baseline and 6 months; multislice computed tomography (MSCT) was performed at 12 months.


Acute procedural success was achieved in 15 of 15 patients receiving a study scaffold. At 12 months, there was no scaffold thrombosis and no major adverse cardiac events directly attributable to the scaffold. At 6 months, in-scaffold LLL (by QCA) was 0.19 ± 0.19 mm; neointimal volume (by IVUS) was 7.19 ± 3.56%, with no evidence of scaffold recoil or late malapposition. Findings were confirmed with OCT and showed uniform, thin neointimal coverage (0.12 ± 0.04 mm). At 12 months, MSCT demonstrated excellent vessel patency.


This study demonstrated the feasibility and efficacy of the DESolve BCS. Results showing low in-scaffold LLL, low % neointimal volume at 6 months, no chronic recoil, and maintenance of lumen patency at 12 months prompt further study. (DESolve First-in-Man; EudraCT number 2011-000027-32).


%DS; BCS; CK; DES; IVUS; LLL; MACE; MI; MSCT; OCT; PLLA; QCA; TLR; bioresorbable coronary scaffold; coronary disease; creatine kinase; drug-eluting; drug-eluting stent(s); imaging; intravascular ultrasound; late lumen loss; major adverse cardiac event(s); multislice computed tomography; myocardial infarction; optical coherence tomography; percent diameter stenosis; poly-l-lactic acid; quantitative coronary angiography; scaffold; stent(s); target lesion revascularization

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center